<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856293</url>
  </required_header>
  <id_info>
    <org_study_id>A8081074</org_study_id>
    <nct_id>NCT04856293</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE OF AN ENCAPSULATED MICROSPHERE FORMULATION (eMS) TO THE FORMULATED CAPSULE (FC) OF CRIZOTINIB IN HEALTHY ADULT PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated&#xD;
      microsphere (eMS) formulation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to overcome the poor taste/palatability associated with the original oral solution&#xD;
      formulation of crizotinib for pediatric patients, an encapsulated microsphere (eMS)&#xD;
      formulation with improved palatability compared with the oral solution and acceptable PK&#xD;
      characteristics was developed.&#xD;
&#xD;
      The primary objective of this study is to establish the bioequivalence of the eMS formulation&#xD;
      to the current commercial formulation, ie, formulated capsule (FC), in adult healthy&#xD;
      participants to support the commercialization of this new formulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma AUCinf after administration of the FC formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1, 2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time&#xD;
Method of Determination:&#xD;
Linear-log trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Cmax after administration of the FC formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1, 2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Maximum plasma concentration&#xD;
Method of Determination:&#xD;
Observed directly from the data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma AUClast after administration of the FC formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1, 2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (Clast)&#xD;
Method of Determination:&#xD;
AUClast + (Clast/kel) Where Clast is the predicted plasma concentration at the last quantifiable time point and kel is the elimination rate constant estimated from the loglinear regression analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma AUCinf after administration of the unencapsulated eMS formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1, 2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Area under the plasma concentration-time profile from time zero extrapolated to infinite time&#xD;
Method of Determination:&#xD;
Linear-log trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Cmax after administration of the unencapsulated eMS formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1, 2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Maximum plasma concentration&#xD;
Method of Determination:&#xD;
Observed directly from the data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma AUClast after administration of the unencapsulated eMS formulation</measure>
    <time_frame>Day 1, Pre-dose, hour 1,2,4,6,8,12,24,48,72,96,144 (Periods 1-3)</time_frame>
    <description>Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (Clast)&#xD;
Method of Determination:&#xD;
AUClast + (Clast/kel) Where Clast is the predicted plasma concentration at the last quantifiable time point and kel is the elimination rate constant estimated from the loglinear regression analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Three Period Treatment Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial, and a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two Period Treatment Sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 250 mg crizotinib dose of the formulated capsule(FC) formulation, a single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>A single 250 mg crizotinib dose of the FC formulation</description>
    <arm_group_label>Three Period Treatment Sequence</arm_group_label>
    <arm_group_label>Two Period Treatment Sequence</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial</description>
    <arm_group_label>Three Period Treatment Sequence</arm_group_label>
    <arm_group_label>Two Period Treatment Sequence</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.</description>
    <arm_group_label>Three Period Treatment Sequence</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be 18 to 55 years of age, inclusive, at the time of signing the&#xD;
             informed consent document (ICD).&#xD;
&#xD;
          2. Male and female of non-childbearing potential participants who are overtly healthy as&#xD;
             determined by medical evaluation including medical history, physical examination, and&#xD;
             laboratory tests.&#xD;
&#xD;
          3. Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          4. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
          5. Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in theICD and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or&#xD;
             allergic disease.&#xD;
&#xD;
          2. Any condition possibly affecting crizotinib absorption (eg, gastrectomy,&#xD;
             cholecystectomy, appendectomy).&#xD;
&#xD;
          3. History of HIV infection, chronic hepatitis B, or hepatitis C; positive testing for&#xD;
             HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or&#xD;
             hepatitis C antibody (HCVAb).&#xD;
&#xD;
          4. Positive COVID-19 test.&#xD;
&#xD;
          5. History of sensitivity to heparin or heparin induced thrombocytopenia.&#xD;
&#xD;
          6. Known history of hypersensitivity to crizotinib or any components of the formulations.&#xD;
&#xD;
          7. Other medical or psychiatric condition: recent or active suicidal ideation/behavior,&#xD;
             laboratory abnormality or conditions related to the COVID-19 pandemic that make the&#xD;
             participant inappropriate.&#xD;
&#xD;
          8. Use of prescription or nonprescription drugs and dietary and herbal supplements within&#xD;
             7 days or 5 half-lives (whichever is longer) prior to the first dose of crizotinib.&#xD;
&#xD;
          9. Previous administration with an investigational drug within 30 days or 5 half-lives&#xD;
             preceding the first dose of crizotinib (whichever is longer).&#xD;
&#xD;
         10. Positive urine drug test or cotinine test.&#xD;
&#xD;
         11. Supine BP &gt;=140 mm Hg (systolic) or &gt;=90 mm Hg (diastolic), following at least 5&#xD;
             minutes of supine rest. If BP &gt;=140 mm Hg (systolic) or &gt;=90 mm Hg (diastolic), BP&#xD;
             should be repeated 2 more times.&#xD;
&#xD;
         12. Any clinically significant abnormality in 12-lead ECG, including QTcF &gt;450 msec,&#xD;
             Computer-interpreted ECGs may be overread by a physician experienced in reading ECGs&#xD;
             before excluding participants.&#xD;
&#xD;
         13. AST or ALT level &gt; (ULN); TBili level &gt;ULN; participants with a history of Gilbert's&#xD;
             syndrome may have direct bilirubin &lt;= ULN; eGFR &lt;90 ml/min/1.73 m2 per CKD-EPI&#xD;
             equation.&#xD;
&#xD;
         14. Male participants who are unwilling or unable to comply with the contraception&#xD;
             requirement.&#xD;
&#xD;
         15. History of alcohol abuse or binge drinking and/or any other illicit drug use or&#xD;
             dependence within 6 months of Screening.&#xD;
&#xD;
         16. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to dosing.&#xD;
&#xD;
         17. Participants who currently smoke.&#xD;
&#xD;
         18. Unwilling or unable to comply with the criteria in the Lifestyle Considerations&#xD;
             section of this protocol.&#xD;
&#xD;
         19. Investigator site staff members or Pfizer employees directly involved in the conduct&#xD;
             of the study, site staff otherwise supervised by the investigator, and their&#xD;
             respective family members.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A8081074</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crizotinib</keyword>
  <keyword>Encapsulated Microsphere Formulation</keyword>
  <keyword>Healthy adult participants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

